1. Home
  2. CCM vs APVO Comparison

CCM vs APVO Comparison

Compare CCM & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concord Medical Services Holdings Limited

CCM

Concord Medical Services Holdings Limited

N/A

Current Price

$3.74

Market Cap

23.8M

Sector

Health Care

ML Signal

N/A

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$1.27

Market Cap

21.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCM
APVO
Founded
1997
2016
Country
China
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.8M
21.7M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
CCM
APVO
Price
$3.74
$1.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.0K
682.4K
Earning Date
09-26-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$51,056,841.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.60
$1.04
52 Week High
$10.77
$298.00

Technical Indicators

Market Signals
Indicator
CCM
APVO
Relative Strength Index (RSI) 33.78 44.21
Support Level $3.71 $1.04
Resistance Level $4.00 $1.42
Average True Range (ATR) 0.21 0.09
MACD -0.03 0.01
Stochastic Oscillator 10.68 48.00

Price Performance

Historical Comparison
CCM
APVO

About CCM Concord Medical Services Holdings Limited

Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: